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Polyagglutination is a condition in which red blood cells (RBCs) 
are agglutinated by normal adult human sera but not by autologous 
or newborn sera. Polyagglutination is caused by changes in the 
RBC membrane that enable patient RBCs to agglutinate with 
normal human sera; this agglutination can interfere with blood 
bank testing. Depending on the cause, polyagglutination may or 
may not be the cause of RBC hemolysis. Lectins and human sera 
can be used to detect polyagglutinable RBCs. Identification of this 
phenomenon can be helpful in providing not only transfusion 
recommendation information for physicians but also information 
associated with pathogens (i.e., Streptococcus pneumoniae) and 
severity of illness. Testing with ABO group–compatible adult 
human sera can determine if a patient’s RBCs are polyagglutinable. 
Further testing with a variey of lectins may identify the kind of 
polyagglutination. Immunohematology 2018;34:113–117.
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Principle and Background
Polyagglutination was first described in 1988 by Peter 
Hermann Stillmark in his doctoral thesis. The agglutinin 
used was isolated from seeds of the castor tree (i.e., ricin) 
and was highly toxic. Ricin became commercially available, 
which prompted Paul Ehrlich to use it for studies in the 1890s 
to establish fundamental principles of immunology. Ehrlich 
found that mice could become tolerant to a lethal dose of ricin 
by repeated small injections of the lectin, creating protective 
antibodies to the ricin.1
Karl Landsteiner detected hemagglutinating activity in 
some nontoxic plant extracts. In 1909, he observed that the 
hemagglutinating activity of certain seed extracts or “lectins” 
was inhibited by either heat-treated serum or by mucin.2 
During the 1940s and 1950s, there was increased research 
in the area of lectin extracts from plant seeds. Some lectins 
showed hemagglutinating activity with all RBCs, and others 
showed blood group–specific activity, such as A or H.
There are two categories of polyagglutination: acquired (T, 
Tk, Th, Tx, acquired B) and inherited (Tr, HEMPAS, Cad, Tn). 
In both categories, the surface of human RBCs can become 
altered by (1) microbial enzyme modification, usually through 
sepsis; (2) homozygosity of rare altered alleles, often due to 
consanguinity; and (3) a disease state such as lymphoma 
or leukemia. This RBC alteration causes panagglutination 
when these RBCs are combined with normal adult human 
sera which contain naturally occurring antibodies to these 
altered antigens but not when they are combined with cord 
sera which do not.3 Understanding the mechanisms by 
which polyagglutinable RBCs occur can help in recognizing 
these conditions when working on patient samples and in 
determining when polyagglutination screening is indicated.
Reagents/Supplies
Reagents Supplies
• Adult group O RBCs
• Phosphate-buffered saline  
(7.0–7.5 pH)
• Lectins (if available): Arachis 
hypogea, Glycine soja, Salvia 
sclarea, Salvia horminum (or 
Dolichos biflores if the patient is 
non–group A)
• Polyagglutinable RBCs (frozen or 
prepared)
• Donor pooled group AB plasma or 
serum 
• Pooled cord serum
• Neuraminidase, 1 IU/mL from Vibrio 
cholera




• 10 × 75 mm tubes
RBCs = red blood cells.
Procedural Steps
Preparing controls
• Treat adult group O RBCs with neuraminidase.
• Pool the serum from three to five cord blood samples.
• Grind up lectin seeds, incubate in 0.9% saline, and harvest the 
supernatant.
Process
• Mix lectin and/or human sera with a 3–5% suspension of patient 
RBCs.
• Incubate at room temperature.
• Centrifuge, and read macroscopically for agglutination.
RBCs = red blood cells.
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Microbial Enzyme Modification
Polyagglutination caused by microbial enzyme 
modification occurs when enzymes excreted from bacteria 
cleave portions of the RBC membrane, exposing hidden 
antigens termed “cryptantigens” on the RBC surface. There 
are many types of polyagglutination due to bacterial action 
including but not limited to T, acquired B, Tk, Th, and Tx. 
Identifying and understanding the type of polyagglutination 
often linked to pathogens can be helpful for the clinician.4,5
T-acTivaTion
During T-activation, the neuraminidase enzyme cleaves 
terminal N-acetylneuraminic acid (NeuAc) from the RBC 
membrane, exposing a hidden crypt or T antigen that can 
agglutinate with naturally occurring IgM anti-T present in 
most adult sera. This phenomenon was first described in 1938 
when the RBCs of a 4-year-old child with bronchopneumonia 
were agglutinated by 15 percent of ABO-compatible human 
sera.6 Anti-T IgM antibodies are absent in newborns and 
form over time in response to T-like antigenic stimulation of 
bacteria from intestinal exposure. This process is analogous 
to the formation of anti-A and anti-B from exposure to A- and 
B-like antigens in the environment.7 Unlike anti-A and anti-B, 
however, the binding of anti-T has not been proven to cause 
hemolysis during the acute disease state. T-activated RBCs 
are agglutinated by human sera and by Arachis hypogea and 
Glycine soja.5,8
acquired B, Tk, Th, Tx 
Acquired B, Tk, Th, and Tx polyagglutination are 
caused by similar processes. Acquired B is associated with 
gastrointestinal (GI) disease and occurs when A1 RBCs 
(N-acetylgalactosamine) are degraded by bacterial enzymes to 
galactosamine and therefore look similar to B RBCs but react 
with human anti-B.9 
Before the advent of monoclonal reagents, human 
polyclonal reagents were used for routine ABO blood group 
testing. These reagents were prepared from human sera 
which contained naturally occurring antibodies to such 
“cryptantigens”. Acquired B polyagglutination caused blood 
group discrepancies in the forward typing results when 
polyclonal reagents were used.10 Tk polyagglutination is also 
associated with GI infection. Bacteria that produce endo-
beta-galactosidase remove galactose residues, exposing 
N-acetylglucosamine in the paragloboside system and causing 
Tk polyagglutination.11 Th and Tx polyagglutination are not as 
well understood as the other types of microbial infection but 
have been associated with bacterial infections of the intestinal 
tract and pneumococcal infections, respectively.12,13
Inheritance of Rare Altered Alleles
Polyagglutination caused by the inheritance of rare, altered 
alleles is associated with increased or altered glycosylation or 
changes in the antigen expression on the RBC surface, which 
causes the RBC to react with naturally occurring antibodies in 
human sera. Examples of inherited polyagglutination include 
but are not limited to Tr, HEMPAS, and Cad. NOR has now 
been assigned to the P1PK blood group system (ISBT 003.004 
or 3.4) and is no longer considered a polyagglutinable state.14,15
Tr
Tr polyagglutination has been shown to be caused by the 
lack of glycosylation of membrane proteins.16 In this case, 
the parents were consanguineous, and the propositus was 
homozygous for the altered allele.
heMPaS 
HEMPAS is an acronym for hereditary erythroblastic 
multinuclearity with a positive acidified serum lysis test and 
is caused by congenital dyserythropoietic anemia type II. The 
RBCs of these individuals react with anti-I and anti-i.17 These 
abnormal RBC membranes result in increased susceptibility 
to lysis and a compensating anemia.18 HEMPAS RBCs react 
with Glycine soja.
cad
Individuals with Cad polyagglutination do not have a 
compensating anemia but have a very strong expression of 
Sda on their RBCs which reacts with weak naturally occurring 
anti-Sda.19–21 Cad+ RBCs react with Glycine soja and Salvia 
horminum.
Polyagglutination and Disease
Polyagglutination has been associated with leukemia in 
some individuals, and Tn polyagglutination characterized 
by persistent mixed-field agglutination has been linked to 
myelocytic leukemia.22 The RBC membrane change is through 
somatic mutation resulting in one cell population lacking 
NeuAc.23 
Tn acTivaTion
Tn activation has been described in healthy individuals 
and some infants. It may be caused by incomplete expression 
of the gene responsible for converting the Tn into T expressed 
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on RBCs.24,25 Incomplete synthesis of T on RBCs in this type 
of polyagglutination causes agglutination with Salvia sclarea, 
Salvia horminum, and Glycine soja.26
Indications
Indications for polyagglutination can come from 
discrepant results obtained during ABO testing caused by the 
naturally occurring antibody (e.g., anti-T) in human polyclonal 
antisera.27 Since the advent of monoclonal reagents, however, 
most examples of polyagglutination are only suspected after 
reviewing the clinical findings of the patient who has suspected 
hemolysis or anemia of unknown origin. Lectins and normal 
adult human sera can be used to detect the surface changes on 
polyagglutinable RBCs. By observing the patterns of reactivity 
of the RBCs in question with human sera and with the various 
lectins, the specific polyagglutinable state of the patient’s RBCs 
can be identified.
Materials
Prepare human sera for testing against patient RBCs by 
pooling the plasma or serum from four to six group AB donors 
drawn within 48 hours. This plasma pool can be stored frozen 
for later use.26
Pooled serum from two to three cord blood samples can 
be used as a negative control for the polyagglutination screen. 
Mix one drop each of group A1 and group B RBCs with two 
drops of pooled cord sera. Incubate at room temperature for 
approximately 5 minutes. Centrifuge, and read macroscopically 
for agglutination. The cord sera should not agglutinate the 
group A1 or group B RBCs. If there is reactivity, cord sera are 
contaminated with maternal antibody and should not be used.28
If lectins are not available commercially, they can be 
extracted from a variety of seeds.29 Salvia horminum lectin 
is also known as annual sage, Salvia sclarea is clary sage, 
Arachis hypogea is from raw peanuts, and Glycine soja (also 
known as Glycine max) is from wild soybean. To prepare the 
lectins, measure 1 g of seeds. Wash, and grind up the seeds 
and then incubate in 5 mL of 0.9 percent saline. Let the 
mixture sit overnight. Centrifuge the mixture, and harvest the 
supernatant.30 To obtain a clear supernatant, run the lectin 
through a filter. 
Quality Control for In-House Prepared Lectins
Although it is relatively easy to create lectins, it is difficult 
to find polyagglutinable RBCs to use as positive controls 
to ensure potency and specificity. T-activated RBCs can be 
prepared by treating normal RBCs with neuraminidase. 
These RBCs can then be used as a positive control for Arachis 
hypogea, for Glycine soja, and for the pooled human plasma. 
To prepare T-activated RBCs, wash adult group O 
RBCs from a single donor source with 0.9 percent saline 
three to four times. Dilute one part neuraminidase with 
nine parts phosphate-buffered saline (PBS) (i.e., one drop of 
neuraminidase with nine drops of PBS). In one tube, mix one 
volume (e.g., three drops) of the packed RBCs with an equal 
volume of diluted neuraminidase. In a second tube, mix one 
volume (e.g., three drops) of the packed RBCs with an equal 
volume of 6 percent albumin to serve as a negative control 
when testing to ensure T-activation has occurred. Incubate 
both tubes at 37°C for approximately 15 minutes, then wash 
three to four times with 0.9 percent saline, and create a 3–5 
percent concentration in 0.9 percent saline.
Test the treated and untreated RBCs with Glycine soja to 
ensure activation of the treated cells and no activation with 
the untreated cells. T-activated RBCs can be stored in liquid 
nitrogen if not used immediately for testing.
Quality Control 
To prepare the positive control, add one drop of T-activated 
RBCs to one drop of each lectin tested. To prepare the negative 
control, add one drop of cord sera to a 3–5 percent suspension 
of the patient’s RBCs. Mix, and incubate all tubes using the 
same time and temperature as specified in the manufacturer’s 
instructions or as determined in the in-house standardization 
of the lectin in use. Centrifuge, and read macroscopically for 
agglutination. 
The T-activated RBCs will react with Arachis hypogea, 
Glycine soja, and the pooled plasma/sera control but will not 
react with Salvia sclarea, Salvia horminum/Dolichos biflores, 
or pooled cord sera. See Table 1.27,30
Procedure
Mix one drop of a 3–5 percent suspension of the patient’s 
RBCs with two drops of pooled donor plasma or sera. If lectins 
are commercially available, mix one drop of the patient’s RBC 
suspension with each lectin following the manufacturer’s 
instructions for amount, time, and temperature indicated. If 
in-house prepared lectins are used, the amount of lectin would 
be dependent upon in-house standardization. Centrifuge, and 
read macroscopically for agglutination.
Detecting polyagglutinable RBCs
116 IMMUNOHEMATOLOGY, Volume 34, Number 3, 2018
C. Melland and C. Hintz
Interpretation
If adult sera are reactive with the RBCs tested and the cord 
sera are nonreactive, the RBCs are polyagglutinable. If the 
adult sera are nonreactive and the cord sera are nonreactive, 
then the RBCs are not polyagglutinable. If the cord sera are 
reactive, then consider spontaneous agglutination due to 
antibodies present in the plasma.
Note that additional lectins are available to help determine 
the specific type of polyagglutination present. Table 1 shows 
examples of lectin reactivity with examples of polyagglutinable 
RBCs.15,31
Limitations
Lectins kits are no longer available from commercial 
manufacturers. Noncommercial lectins should be used for 
testing with the appropriate controls tested the day of use. 
Cad and Tn polyagglutinable RBCs are needed to create 
positive controls for Salvia horminum and Salvia sclarea. The 
unavailability of these polyagglutinable RBCs is problematic 
for using these lectins. If lectins are not made with the proper 
solutes, they cannot be stored frozen.
Patient RBCs that are not completely polyagglutinated 
or are transiently polyagglutinable may not react by testing 
with lectins or human sera. Conversely, some lectins have 
antibacterial activity and may agglutinate RBCs coated with 
bacterial polysaccharides. This reactivity is not the same 
reactivity caused by the state of polyagglutination and justifies 
the use of pooled human sera to support the polyagglutination 
test.32
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